CDC Studies Show Vaccine Protection Wanes Over Time, Less Effective Against Delta Variant By
The Centers for Disease Control and Prevention Wednesday released three studies on the effectiveness of the Pfizer and Moderna vaccines. A UK study released Tuesday showed people with “breakthrough” infections carry as much virus as the unvaccinated.
The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It’s free.
New COVID vaccine data released Wednesday by the Centers for Disease Control and Prevention (CDC) confirms COVID vaccine effectiveness against infection has decreased over time, and is less effective in combating the Delta variant.
Now is your chance to support Gospel News Network.
We love helping others and believe that’s one of the reasons we are chosen as Ambassadors of the Kingdom, to serve God’s children. We look to the Greatest Commandment as our Powering force.
“The data we will publish today and next week demonstrate the vaccine effectiveness against SARS CoV-2 infection is waning,” CDC Director Dr. Rochelle Walensky said during a press briefing. “And even though our vaccines are currently working well to prevent hospitalizations, we are seeing concerning evidence of waning vaccine effectiveness over time, and against the Delta variant.”
The CDC released three new studies focusing on the vaccines’ effectiveness in light of the Delta variant.
As COVID—especially Delta variant—surges among fully vaccinated, Brian Hooker, Ph.D., said the more variant deviates from original sequence used for vaccine, the less effective vaccine will be on variant.
SUBSCRIBE #TheDefender: https://t.co/zL66Edfiw5https://t.co/ukuh6XlMSu
— Robert F. Kennedy Jr (@RobertKennedyJr) August 4, 2021
One study assessed Pfizer and Moderna’s effectiveness over time against infections among nursing home residents, and found it dropped from 75% pre-Delta to 53% when Delta became dominant. The study didn’t differentiate between asymptomatic, symptomatic and severe infections.
Another study used data from 21 hospitals to estimate the effectiveness of Pfizer and ModernamRNA vaccines against hospitalization over time. Among 1,129 patients who received two doses of a mRNA vaccine, vaccine effectiveness was 86% 2 to12 weeks after vaccination and 84% at 13 to 24 weeks.
The third study, using New York state data, found all three vaccines’ effectiveness against infection dropped from 92% in early May to 80% at the end of July, but the effectiveness against hospitalization remained relatively stable.
Data from the three reports in the CDC’s Morbidity and Mortality Weekly Report, helped convince the Biden administration to recommend booster shots to people eight months after receiving their second dose, despite no completed late-stage clinical trials assessing the safety, efficacy and immunogenicity of a third dose.
Watch Vaxxed II and Sign-Up for Q&A Thursday 1 p.m. PT/4 p.m. ET
Under Biden’s plan announced Wednesday, boosters will start being administered Sept. 20 — pending authorization of a third dose from the U.S. Food and Drug Administration and the CDC’s advisory committee.
Health experts said the CDC data should make the case that it’s more important to get initial doses to the unvaccinated, and boosters to immunocompromised people and nursing home residents, rather than to the entire population.
“I mostly care about hospitalizations, I don’t care about infections because this is not what we’re using vaccines for. We’re not trying to stop infections, and there’s no evidence that a third booster will stop infections,” said Jennifer Nuzzo, an epidemiologist and senior scholar at the Johns Hopkins Center for Health Security.
Nuzzo said people need to remember vaccines aren’t force fields. “They don’t prevent infections,” she said. “They train your immune system to respond quickly to infections and hopefully limit the number of cells that get infected. They work to limit infections to prevent severe disease, hopefully to keep people out of the hospital.”
